拉米夫定联合齐多夫定或司他夫定治疗前后的脑脊液β2微球蛋白、单核细胞趋化蛋白-1及可溶性肿瘤坏死因子α受体

Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.

作者信息

Enting R H, Foudraine N A, Lange J M, Jurriaans S, van der Poll T, Weverling G J, Portegies P

机构信息

Department of Neurology H2-214, Academic Medical Center, University of Amsterdam, Netherlands.

出版信息

J Neuroimmunol. 2000 Jan 24;102(2):216-21. doi: 10.1016/s0165-5728(99)00219-2.

DOI:10.1016/s0165-5728(99)00219-2

PMID:10636491

Abstract

CSF levels of beta2-microglobulin (b2m), monocyte chemotactic protein-1 (MCP-1), soluble tumor necrosis factor receptors (sTNFRs), and HIV-1 RNA were determined in 16 neurologically asymptomatic HIV-1 infected patients before and 12 weeks after treatment with lamivudine plus zidovudine or stavudine. b2m levels were significantly higher in patients (1.7 mg/l) compared with controls (0.8 mg/l) (P < 0.001), and decreased to 1.1 mg/l during treatment (P = 0.001). MCP-1 levels were low, and did not change during treatment. Levels of sTNFR type I were elevated in patients (0.92 ng/ml) compared to controls (0.30 ng/ml) (P = 0.03), but did not change during treatment. Levels of sTNFR type II were below the limit of detection in most patients and controls. In conclusion, CSF levels of b2m and HIV-I RNA, but not sTNFRs or MCP-1, are candidate surrogate markers of treatment efficacy in early CNS infection.

摘要

在16例神经系统无症状的HIV-1感染患者中，在接受拉米夫定加齐多夫定或司他夫定治疗前及治疗12周后，测定了脑脊液中β2-微球蛋白（b2m）、单核细胞趋化蛋白-1（MCP-1）、可溶性肿瘤坏死因子受体（sTNFRs）和HIV-1 RNA的水平。与对照组（0.8mg/l）相比，患者的b2m水平显著更高（1.7mg/l）（P<0.001），且在治疗期间降至1.1mg/l（P = 0.001）。MCP-1水平较低，且在治疗期间未发生变化。与对照组（0.30ng/ml）相比，患者中I型sTNFR水平升高（0.92ng/ml）（P = 0.03），但在治疗期间未发生变化。大多数患者和对照组中II型sTNFR水平低于检测限。总之，脑脊液中b2m和HIV-1 RNA水平，而非sTNFRs或MCP-1水平，是早期中枢神经系统感染治疗疗效的候选替代标志物。